AMR Davos Compact 2025

7 Appendix : Relevant paragraphs from the United Nations Political Declaration on AMR Innovation and Access (Anti microbials, Diagnostics and Vaccines) 45. Call on the Quadripartite organizations, in collaboration with Member States upon their request and other stakeholders including private sector and partnerships, such as Global Antibiotic Research and Development Partnership (GARDP), through the SECURE initiative, and the Global Drug Facility, as applicable, to take steps to increase global access to and appropriate use of antimicro bials in settings with the highest unmet need, including by aligning regional and subregional medicine registration and reforming regulatory and policy pathways, as necessary, to accelerate authorization of safe and effective products, especially for new antimicrobials, and to consider implementing new, sustainable procurement models, such as pooled procurement, tiered pricing and by supporting measures to ensure the resilience of supply chains for health products; 84. Recognize the benefits of public -private partnerships in the development of and access to antimicrobials, vaccines, diagnostics and alternatives to antimicrobials and in contributing to supply chain sustainability, and take note of the work of the Combatting Antibiotic -Resistant Bacteria Biopharmaceutical Accelerator (CARB- X) and the Global Antibiotic Research and Development Partnership (GARDP); 86. Explore, encourage and promote a range of innovative incentives and financing mechanisms for multisectoral health research and development to address antimicrobial resistance, and a stronger and transparent partnership between the public and the private sectors as well as academia and the scientific community, acknowledging the important role played by the private sector in research and development of innovative medicines, while recognizing the need for increasing public health -driven research and devel opment that is needs- driven and evidence- based, guided by the core principles of safety, availability, affordability, effectiveness, efficiency, equity and accessibility, as well as appropriate incentives, including push and pull incentives, in the development of new health products and technologies, while ensuring that mechanisms are in place for equitable access, particularly in developing countries; 88. Improve availability, affordability and efficiency of health products by increasing transparency of prices of medicines, vaccines, medical devices, diagnostics, assistive products, cell - and gene - based therapies and other health technologies across the val ue chain, including through improved regulations and building constructive engagement and a stronger partnership with relevant stakeholders, including industries, the private sector and civil society, in accordance with national and regional legal fram eworks and contexts, to address the global concern about the high prices of some health products and in this regard encourage the World Health Organization to continue its